N/A
Completed N=38
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Epilepsy · Psychiatric or Mood Diseases or Conditions
Source: ClinicalTrials.gov NCT01231646 ↗
Enrolled (actual)
38
Serious AEs
—
Results posted
Oct 2015
Primary outcomePrimary: Levels of Folate Receptor Autoantibodies — 35.33; 35.21; 44.3; 41.81 ug/mL
Summary
Women who take folate (folic acid) before getting pregnant can lower the risk of giving birth to infant with certain birth defects. However, some medications may affect the action of folate. The purpose of this study is to compare the effect of two anti-epileptic drugs on how folate works in our body.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Levels of Folate Receptor Autoantibodies |
35.33; 35.21; 44.3; 41.81; 79.62; 77.06 | — |
Eligibility Criteria
Inclusion Criteria
- Women ages 18-50 years inclusive who are taking valproate or lamotrigine for neurologic or psychiatric conditions
- Valproate of lamotrigine must be used as monotherapy at stable doses for 6 weeks prior to the study for the neurologic or psychiatric illness; medications taken for other reasons are not excluded.
Exclusion Criteria
- Women with prior exposure to valproate or lamotrigine if they are taking lamotrigine or valproate respectively.
Data sourced from ClinicalTrials.gov (NCT01231646). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.